RT Journal
A1 Braillon A
T1 Generic competition in a flawed system: Pill them, bill them
JF Archives of Internal Medicine
JO Archives of Internal Medicine
YR 2012
FD October 22
VO 172
IS 19
SP 1522
OP 1523
DO 10.1001/archinternmed.2012.4389
UL http://dx.doi.org/10.1001/archinternmed.2012.4389
AB 
The license of some corporations to manipulate the system to suit their interests requires an enduring complacency of the system. Recently, the US Food and Drug Administration, despite the lack of evidence for benefit, granted a new marketing authorization for the 23-mg dose of donepezil hydrochloride in the treatment of Alzheimer disease.2 This allows Pfizer to avoid generic competitors, since the patent for donepezil, first approved in 1996, expired in November 2010. Lastly, could this be a reason why so many physicians prescribe their patients with costly medicines when less expensive ones are available?